 Garth Wright
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 2 | 2022 | 325 | 0.240 |
Why?
| | Heart Failure | 3 | 2025 | 2323 | 0.240 |
Why?
| | Genetic Therapy | 2 | 2025 | 313 | 0.230 |
Why?
| | Reimbursement Mechanisms | 1 | 2025 | 79 | 0.210 |
Why?
| | Contraception, Postcoital | 1 | 2023 | 9 | 0.200 |
Why?
| | Medicaid | 2 | 2025 | 464 | 0.200 |
Why?
| | Hemophilia B | 1 | 2023 | 65 | 0.190 |
Why?
| | Abortion, Induced | 1 | 2023 | 110 | 0.170 |
Why?
| | Hemophilia A | 1 | 2023 | 146 | 0.170 |
Why?
| | Anemia, Sickle Cell | 1 | 2025 | 312 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 603 | 0.160 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 206 | 0.160 |
Why?
| | Nausea | 1 | 2020 | 111 | 0.150 |
Why?
| | Antiemetics | 1 | 2020 | 48 | 0.150 |
Why?
| | Shock, Septic | 1 | 2022 | 216 | 0.150 |
Why?
| | Vomiting | 1 | 2020 | 131 | 0.150 |
Why?
| | Decision Support Systems, Clinical | 1 | 2023 | 267 | 0.150 |
Why?
| | Patient Acceptance of Health Care | 1 | 2025 | 880 | 0.140 |
Why?
| | Labetalol | 1 | 2018 | 6 | 0.140 |
Why?
| | Adrenergic Antagonists | 1 | 2018 | 5 | 0.140 |
Why?
| | Hydralazine | 1 | 2018 | 6 | 0.140 |
Why?
| | Obesity, Morbid | 1 | 2022 | 288 | 0.140 |
Why?
| | Anticoagulants | 2 | 2022 | 726 | 0.130 |
Why?
| | Heparin | 1 | 2019 | 242 | 0.130 |
Why?
| | Pneumonia | 1 | 2023 | 627 | 0.130 |
Why?
| | Alcoholism | 1 | 2023 | 813 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 551 | 0.120 |
Why?
| | Telemedicine | 1 | 2025 | 957 | 0.120 |
Why?
| | Vasodilator Agents | 1 | 2018 | 329 | 0.120 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 601 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1075 | 0.100 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 512 | 0.100 |
Why?
| | Retrospective Studies | 8 | 2025 | 17104 | 0.100 |
Why?
| | Stroke | 1 | 2022 | 1259 | 0.100 |
Why?
| | Hospitalization | 2 | 2023 | 2440 | 0.090 |
Why?
| | Cost-Benefit Analysis | 2 | 2025 | 637 | 0.080 |
Why?
| | Blood Pressure | 1 | 2018 | 1763 | 0.080 |
Why?
| | Hypertension | 1 | 2018 | 1259 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2194 | 0.070 |
Why?
| | Colorado | 3 | 2025 | 4554 | 0.070 |
Why?
| | Administration, Intravenous | 2 | 2020 | 170 | 0.070 |
Why?
| | Administration, Oral | 2 | 2022 | 847 | 0.070 |
Why?
| | Nebraska | 1 | 2025 | 21 | 0.060 |
Why?
| | Wyoming | 1 | 2025 | 27 | 0.060 |
Why?
| | Hemorrhage | 2 | 2022 | 807 | 0.060 |
Why?
| | Humans | 12 | 2025 | 144298 | 0.060 |
Why?
| | Markov Chains | 1 | 2025 | 130 | 0.050 |
Why?
| | Models, Economic | 1 | 2025 | 61 | 0.050 |
Why?
| | Aged | 5 | 2025 | 25901 | 0.050 |
Why?
| | Alabama | 1 | 2023 | 33 | 0.050 |
Why?
| | Contraceptives, Oral | 1 | 2023 | 37 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2025 | 1174 | 0.050 |
Why?
| | Levonorgestrel | 1 | 2023 | 34 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2022 | 8265 | 0.050 |
Why?
| | Cardiology | 1 | 2025 | 359 | 0.040 |
Why?
| | Stroke Volume | 1 | 2025 | 650 | 0.040 |
Why?
| | Middle Aged | 5 | 2025 | 35892 | 0.040 |
Why?
| | Vasopressins | 1 | 2022 | 60 | 0.040 |
Why?
| | Thinness | 1 | 2022 | 98 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 144 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 195 | 0.040 |
Why?
| | Warfarin | 1 | 2022 | 171 | 0.040 |
Why?
| | Granisetron | 1 | 2020 | 6 | 0.040 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2020 | 5 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2022 | 267 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2025 | 732 | 0.030 |
Why?
| | Drug Utilization Review | 1 | 2018 | 61 | 0.030 |
Why?
| | Male | 5 | 2025 | 72263 | 0.030 |
Why?
| | Hospitals, University | 1 | 2018 | 176 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2020 | 545 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2019 | 202 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 193 | 0.030 |
Why?
| | United States | 2 | 2025 | 15979 | 0.030 |
Why?
| | Female | 5 | 2025 | 78137 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 241 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2886 | 0.030 |
Why?
| | Acute Disease | 1 | 2018 | 1029 | 0.030 |
Why?
| | Primary Health Care | 1 | 2025 | 1728 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2012 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 14092 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2019 | 912 | 0.020 |
Why?
| | Critical Illness | 1 | 2019 | 886 | 0.020 |
Why?
| | Adult | 3 | 2020 | 40408 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 7112 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2917 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1359 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5948 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 7128 | 0.020 |
Why?
| | Neoplasms | 1 | 2020 | 2860 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10783 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 11713 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22370 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|